Long non-coding RNA RP3-380B8.4 facilitates tumor malignancy, liver metastasis and shapes an immunosuppressive tumor microenvironment in colorectal cancer.
Abstract
Background
Long non-coding RNAs (lncRNAs) participate in colorectal cancer (CRC) progression and immune regulation. However, the biological functions of lncRNA RP3-380B8.4 (RP3) in CRC and its relationship with the tumor immune microenvironment remain unclear.
Methods
RP3 expression in CRC was assessed using public datasets and validated by in situ hybridization (ISH). We further examined the expression levels and intracellular localization of RP3 in CRC cells by qRT-PCR. The effect of RP3 on the cell growth, migration, invasion and epithelial-to-mesenchymal transition (EMT) was investigated by in vitro experiments and western blot. In vivo experiments confirmed that RP3 potentiated tumor growth and liver metastasis in CRC. We predicted the mechanism by RNA-seq, and confirmed them by western blot. The impact of RP3 on the tumor immune microenvironment was analyzed by bioinformatics analysis and flow cytometry.
Results
RP3 was substantially elevated in CRC tissues and associated with poor prognosis. RP3 overexpression increased CRC cell proliferation, migration, invasion, and EMT in vitro. RP3 overexpression accelerated orthotopic colorectal cancer growth and liver metastasis in nude mice. On the contrary, knockdown of RP3 achieved the opposite effect. Mechanistically, gene set enrichment analysis (GSEA) and western blot analysis revealed that RP3 overexpression is associated with enrichment of MYC target gene programs and elevated c-Myc protein levels in colorectal cancer. Furthermore, overexpression of RP3 significantly reduced the infiltration of CD8+ T cells in the tumor, while inhibiting the polarization of macrophages toward the CD86-positive (M1-like) phenotype. Conversely, knockdown of RP3 effectively ameliorated this tumor immunosuppressive microenvironment.
Conclusions
RP3 facilitates CRC proliferation and metastasis and exerts immunosuppression in the tumor microenvironment. These findings implicate RP3 as a candidate regulator in CRC whose mechanistic and therapeutic potential requires further validation.